Recent Antimicrobials Celebrated as a 'Turning Point' in Combating Antibiotic-Resistant Gonorrhoea
The first new treatments for gonorrhoea in many years are being hailed as a "huge turning point" in the effort against drug-resistant strains of the infection, according to researchers.
A Worldwide Health Concern
Gonorrhoea infections are increasing worldwide, with data suggesting more than 82 million instances per year. Especially elevated rates are seen in Africa and countries within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have hit a historical peak, while figures across Europe in 2023 were three times higher compared to the rates from 2014.
“The approval of new treatments for gonorrhoea is an critical and opportune development in the context of growing infection rates, escalating drug resistance and the extremely scarce therapeutic options presently on offer.”
Health officials are deeply concerned about the increase in drug-resistant strains. The WHO has classified it as a "critical concern". Recent surveillance showed that resistance to standard treatments like cefixime and ceftriaxone increased dramatically between 2022 and 2024.
A Pair of Novel Treatment Options Gain Approval
One new antibiotic, also known as Nuzolvence, was authorized by the US FDA in mid-December for treating gonorrhoea. This STI can lead to significant complications, including infertility. Experts anticipate that targeted use of this new drug will help delay the development of resistance.
Gepotidacin, developed by the pharmaceutical company GlaxoSmithKline, also received approval in close succession. This drug, which is employed against UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.
A Novel Development Model
Zoliflodacin was the result of a new, not-for-profit approach for medication research. The non-profit organisation GARDP collaborated with the drug firm its industry partner to see it through.
“This approval signifies a major breakthrough in the treatment of multidrug-resistant gonorrhoea, which previously has been evolving faster than medical innovation.”
Research Study Results and Worldwide Availability
Based on findings detailed in a prominent scientific publication, the new drug cured the vast majority of genital gonorrhoea infections. This puts it on an similar efficacy with the existing first-line therapy, which uses two antibiotics. The study involved hundreds of volunteers from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.
Through the arrangement of its collaboration, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.
Medical professionals directly involved have shared optimism. The availability of a single-dose, oral treatment such as this is hailed as a "critical tool" for gonorrhoea control. This is viewed as vital to lessen the impact of the illness for individuals and to halt the transmission of untreatable gonorrhoea around the world.
